Seeking Alpha

Clearside Biomedical Announces Publication of Consensus Guidelines for Drug Delivery via Suprachoroidal Space (SCS®) Injection in Leading Peer-Reviewed Industry Journal, RETINA®

- Current Clinical Evidence and Physician Experience Support SCS Injection as a Safe and Effective Method for Delivering Retinal and Choroidal Therapeutics - The publication, entitled, “Suprachoroidal ...
Nasdaq

Clearside Biomedical Highlights CLS-AX Progress and Suprachoroidal Drug Delivery Innovations at ARVO 2025 Meeting

Clearside Biomedical presented data on CLS-AX and its SCS delivery platform at the ARVO 2025 Meeting, highlighting treatment advancements for retinal diseases. Clearside Biomedical, Inc. has announced ...
Seeking Alpha

Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space (SCS®) Delivery Platform and Promising Ophthalmology Pipeline

- Proven In-Office, Repeatable, Non-Surgical Procedure for the Targeted Delivery of a Wide Variety of Therapies for Serious Retinal Diseases - - CLS-AX Phase 3-Ready Asset with Global Investigator ...